PDA

View Full Version : Hexarelin and prolactin...Do I need pct?



pimphandstrong
07-01-2009, 06:29 PM
OK.....

I am a few days shy of my last pin of IGF and I plan to run 100 mcg of Hexarelin every day next.

Am I gonna grow jugs and create my own protein shakes, or will I be ok at that low of a dose.

What type of conlactin (my bad) should I get. I have about 3 weeks to get my hands on it, unless I need to begin running it alongside the hex.

Thanks y'all......

pimphandstrong
07-02-2009, 11:41 PM
It's my understanding that hex causes shut down of test and prolactin can lead to gyno.

Cabergoline run alongside it prevents this.

Presser
07-03-2009, 06:50 AM
bump? not sure about that stuff brutha

pimphandstrong
07-03-2009, 11:20 AM
Out of AAS, I might go for EQ, or Prop, but don't know if I'm willing to take that leap to the dark side.

I love IGF and know a dude that gives 3 for 2 and kicks down free ephedra, but I know I have to switch things up a bit.

From the vets, does your body continue to respond if you run IGF year-round?

That's really why I'm doin Hex....to reset my natural IGF, but is this needed?

ecw16
07-05-2009, 04:44 PM
I've run hex at 500mcg a day for 4weeks on 4weeks off for a 3 month period and no negative sides whatsoever. I cannot recall seeing anywhere that a peptide shuts down test or causes gyno issues. Could be wrong, but my blood tests never showed any negative sides like that.

I've been running long igf for more than a year straight now, 80mcg a day pwo with positive results. Do as much as you can stand (afford) brother...

Here's a little snippet of info in chronic Hex use.

The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.

Rahim A (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rahim%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), O'Neill PA (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22O%27Neill%20PA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Shalet SM (http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shalet%20SM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus).
Department of Endocrinology, Christie Hospital, Withington, Manchester, UK.
OBJECTIVE: With the development of growth hormone (GH) releasing agents and their use in human subjects, it is clear that these agents are not specific for GH release. More recent studies in humans have demonstrated acute increases in adrenocorticotrophic hormone (ACTH), cortisol and prolactin (PRL) after boluses of intravenous or subcutaneous GHRPs. The potential adverse effects of repeated episodes of transient hyperprolactinaemia and hypercortisolaemia during long-term therapy with growth hormone releasing peptides (GHRPs) and similar agents have raised concern. We have therefore assessed the impact of chronic hexarelin administration on the pituitary-adrenal axis and serum prolactin levels. DESIGN: Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks. The ACTH, cortisol and PRL responses to the morning subcutaneous injection of hexarelin were assessed. Hexarelin was administered at time 0 and blood samples were taken at -10, 0, 10, 20, 30, 40, 50, 60, 90, 120, 170 and 180 min. The ACTH and PRL responses were assessed at baseline and after 16 weeks of therapy. The cortisol response was assessed at baseline, 16 weeks and also 4 weeks after completion of hexarelin therapy. Basal levels of cortisol binding globulin (CBG), 24-h urinary free cortisol (UFC) estimations, thyroid stimulating hormone (TSH) and total thyroxine (TT4) were performed at baseline, weeks 16 and 20. RESULTS: The mean (+/- SEM) area under the cortisol curve (AUCCORT) at baseline, week 16 and week 20 were 1506 (+/- 77) nmol/l/h, 1222 (+/- 92) nmol/l/h and 1586 (+/- 58) nmol/l/h, respectively. There was a significant change in AUCCORT over the study period (P = 0.008). Compared with baseline, AUCCOPRT had decreased significantly (P < 0.05) after 16 weeks of hexarelin therapy. Four weeks after completion of hexarelin therapy, the AUCCORT increased significantly compared with AUCCORT at week 16 (P < 0.01) and was no longer significantly different from baseline values. There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period. The mean (+/- SEM) area under the PRL curve (AUCPRL) at the baseline and week 16 were 624 (+/- 82) mU/l/h and 641 (+/- 83) mU/l/h, respectively. There was no significant change in AUCPRL over the study period (P = 0.35). CONCLUSION: The present study demonstrates clearly that in this hexarelin dosage regimen, over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur. In fact the impact of chronic hexarelin therapy on the pituitary-adrenal axis, i.e. decreased AUCCORT, contradict the findings reported after acute hexarelin administration and cannot be explained by changes in CBG. The lack of change in UFC, however, suggests that these changes are unlikely to be of clinical significance although the underlying mechanism requires further study.

pimphandstrong
07-05-2009, 06:20 PM
AAS just ain't my bag, but I'm trying to figure out how to run IGF, Hex, GHRP 2 and 6 and 176-191.

I start 176-191 next week, along with Cabergoline.

Thanks for the responses. Few people have used frags and it takes weeks to get responses.

Hey, what kind of results did you get from Hex?

ecw16
07-05-2009, 11:28 PM
Body, I'd be willing to bet that in the cases you've seen, the users were also taking AAS or an over the counter test booster. Can you tell me what peptide they were taking that induced the gyno? I perform a lot of research with peptides, the more I know the better.

ecw16
07-05-2009, 11:43 PM
Pimp. I ran the hex just for experiments sake and noticed some strength gains and fat loss. Just adding the hex and changing nothing else. It does work, but it is a slow process.

pimphandstrong
07-06-2009, 09:22 PM
It's da kine that you spray into your mouth. I wish I knew how much each spray equls. It's a 30 ml bottle. Tastes like pure sugar. Who knows....maybe it is!?

I am pinning Hex at 80 mcg am and 80 mcg pm and have it reconned with NACL and dang that's a much easier pin than AA. No sting, no lump.

Tomorrow I start 176-191 at 150 mcg am and 150 mcg pm.

At the least, I will have no more ab fat cuz I will have completely perforated my gut. Ha!

Feedback on cabergoline spray dosing would be preeshiated.

pimphandstrong
07-07-2009, 07:23 PM
Sprayed 2 shots.

My research indicated that, in addition to diminishing prolactin, Cabergoline would increase ejaculatory volume and decrease the amount of time the dong takes to get hard again after the nut.

I thought nothing of it, but last night I was rudely awakened by an irrepressable resurgance of repeated boners that kept wakin my ass up. As a rule, morning wood should begin at 4 AM, not 12, 2, and 4!

saudades
07-08-2009, 03:16 PM
IGF and MGF specifically.

I ran IGF solo before and had pre-gyno symptoms. Im sensitive as hell also though. I have a few training partners who encountered similar issues on about 40-60mcgs per day.

Why it happens is a good question. Doesn't make complete sense to me, but I guess at any rate when you adjust one level in the body, another is bound to adjust as well...So who knows??

This is true, IGF and MGF can cause pre-gyno symptoms in some people. However, I don't think hexarelin would cause the same effects since it is a different peptide completely.

Presser
09-19-2018, 09:34 AM
I've run hex at 500mcg a day for 4weeks on 4weeks off for a 3 month period and no negative sides whatsoever. I cannot recall seeing anywhere that a peptide shuts down test or causes gyno issues. Could be wrong, but my blood tests never showed any negative sides like that.

I've been running long igf for more than a year straight now, 80mcg a day pwo with positive results. Do as much as you can stand (afford) brother...

Here's a little snippet of info in chronic Hex use.

The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.

Rahim A (https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rahim%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), O'Neill PA (https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22O%27Neill%20PA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus), Shalet SM (https://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shalet%20SM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus).
Department of Endocrinology, Christie Hospital, Withington, Manchester, UK.
OBJECTIVE: With the development of growth hormone (GH) releasing agents and their use in human subjects, it is clear that these agents are not specific for GH release. More recent studies in humans have demonstrated acute increases in adrenocorticotrophic hormone (ACTH), cortisol and prolactin (PRL) after boluses of intravenous or subcutaneous GHRPs. The potential adverse effects of repeated episodes of transient hyperprolactinaemia and hypercortisolaemia during long-term therapy with growth hormone releasing peptides (GHRPs) and similar agents have raised concern. We have therefore assessed the impact of chronic hexarelin administration on the pituitary-adrenal axis and serum prolactin levels. DESIGN: Each subject received twice-daily subcutaneous hexarelin therapy (1.5 micrograms/kg body weight) for 16 weeks. The ACTH, cortisol and PRL responses to the morning subcutaneous injection of hexarelin were assessed. Hexarelin was administered at time 0 and blood samples were taken at -10, 0, 10, 20, 30, 40, 50, 60, 90, 120, 170 and 180 min. The ACTH and PRL responses were assessed at baseline and after 16 weeks of therapy. The cortisol response was assessed at baseline, 16 weeks and also 4 weeks after completion of hexarelin therapy. Basal levels of cortisol binding globulin (CBG), 24-h urinary free cortisol (UFC) estimations, thyroid stimulating hormone (TSH) and total thyroxine (TT4) were performed at baseline, weeks 16 and 20. RESULTS: The mean (+/- SEM) area under the cortisol curve (AUCCORT) at baseline, week 16 and week 20 were 1506 (+/- 77) nmol/l/h, 1222 (+/- 92) nmol/l/h and 1586 (+/- 58) nmol/l/h, respectively. There was a significant change in AUCCORT over the study period (P = 0.008). Compared with baseline, AUCCOPRT had decreased significantly (P < 0.05) after 16 weeks of hexarelin therapy. Four weeks after completion of hexarelin therapy, the AUCCORT increased significantly compared with AUCCORT at week 16 (P < 0.01) and was no longer significantly different from baseline values. There were no significant changes in UFC (P = 0.3), basal cortisol measurements (P = 0.19), area under the ACTH curve (AUCACTH) (P = 0.24) or CBG (P = 0.6) over the study period. The mean (+/- SEM) area under the PRL curve (AUCPRL) at the baseline and week 16 were 624 (+/- 82) mU/l/h and 641 (+/- 83) mU/l/h, respectively. There was no significant change in AUCPRL over the study period (P = 0.35). CONCLUSION: The present study demonstrates clearly that in this hexarelin dosage regimen, over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur. In fact the impact of chronic hexarelin therapy on the pituitary-adrenal axis, i.e. decreased AUCCORT, contradict the findings reported after acute hexarelin administration and cannot be explained by changes in CBG. The lack of change in UFC, however, suggests that these changes are unlikely to be of clinical significance although the underlying mechanism requires further study.

Long term Hexarelin use and its mechanism of action or side effects on the endocrine system as it pertains to prolactin excretion